Hsp90AB1在非小细胞肺癌中高表达并且与肺腺癌患者不良预后相关

背景与目的 热休克蛋白90AB1(heat shock protein 90 kDa alpha, class B member 1, Hsp90AB1)是ATP依赖的高度保守的分子伴侣,在多种肿瘤细胞中过表达。在肿瘤发生发展的信号传导通路中起着重要作用的一些分子,如表皮生长因子受体(epidermal growth factor receptor, EGFR)、人类表皮生长因子受体-2(human epidermal growth factor receptor-2, HER2)等,均是Hsp90AB1的底物蛋白。Hsp90AB1与这些底物蛋白相互作用并参与细胞的多种病理生理过程。本研究通过检测Hsp90AB1在非小细胞肺癌(non-small cell lung cancer, NSCLC)组织中的蛋白表达情况以初步探讨其临床意义。 方法 采用组织微阵列和免疫组织化学染色的方法检测Hsp90AB1在213例NSCLC及相应癌旁正常肺组织中的蛋白表达,并分析Hsp90AB1的表达与NSCLC临床病理参数及患者预后的关系。 结果 Hsp90AB1在肺癌组织中的表达水平(阳性率54.0%)高于在正常肺组织中的表达水平(阳性率0.0%,P < 0.001)。Hsp90AB1在肺腺癌中的表达阳性率为61.2%,高于肺鳞癌组织37.9%(P=0.002),并且其高表达与肺腺癌患者的不良预后相关(P=0.032)。Hsp90AB1蛋白表达水平与临床分期、淋巴结转移、病理分级等因素无关(P > 0.05)。 结论 Hsp90AB1在NSCLC组织中高表达,并且其表达水平与肺癌的病理类型及肺腺癌患者总生存期相关。

[1]  M. Socinski,et al.  The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells , 2015, Cancers.

[2]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Xiangliang Zhang,et al.  High Expression of Heat Shock Protein 90 Is Associated with Tumor Aggressiveness and Poor Prognosis in Patients with Advanced Gastric Cancer , 2013, PloS one.

[4]  Dongshu Du,et al.  Orexin A regulates cardiovascular responses in stress-induced hypertensive rats , 2013, Neuropharmacology.

[5]  C. Ramos,et al.  The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics. , 2012, Journal of proteomics.

[6]  J. Soh,et al.  Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. , 2012, Lung cancer.

[7]  L. Shen,et al.  Adenosine A(2A)R modulates cardiovascular function by activating ERK1/2 signal in the rostral ventrolateral medulla of acute myocardial ischemic rats. , 2011, Life sciences.

[8]  Alison Stopeck,et al.  HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab , 2011, Clinical Cancer Research.

[9]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[10]  S. Lindquist,et al.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights , 2010, Nature Reviews Molecular Cell Biology.

[11]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Hong Zhang,et al.  Targeting multiple signal transduction pathways through inhibition of Hsp90 , 2004, Journal of Molecular Medicine.

[13]  K. Jhaveri,et al.  HSP90 inhibitors for cancer therapy and overcoming drug resistance. , 2012, Advances in pharmacology.

[14]  L. Neckers,et al.  Hsp 90 Molecular Chaperone Inhibitors : Are We There Yet ? , 2011 .

[15]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.